# A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

> **NCT04270747** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 576 (actual)

## Conditions studied

- Neovascular (Wet) Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** ABP 938
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT04270747
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-22
- **Primary completion:** 2022-07-18
- **Final completion:** 2023-01-30
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270747, "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04270747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*